Checking consistency of automated ILD extent measurements on chest CT
Official title: Evaluation of the Reproducibility of the Automated Measurement of the Extent of Interstitial Lung Disease on Chest CT
Run by Assistance Publique - Hôpitaux de Paris · NCT06743022 · Data updated 2026-11-12
We will test whether automated software gives consistent measurements of how much interstitial lung disease an adult has on same-day chest CT scans for people with idiopathic pulmonary fibrosis or connective tissue disease–related ILD.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 6 sites (Paris, IDF and 5 other locations) |
| Status | Recruiting |
| Started | June 24, 2025 |
| Main results expected | August 2027 |
| Study ends | September 2027 |
| Registry record updated | September 22, 2026 |
| Trial ID | NCT06743022 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with known ILD due to idiopathic pulmonary fibrosis or connective tissue disease who are followed at the participating hospitals, scheduled for a routine chest CT, covered by French social security, and able to give informed consent.
✕Probably not a fit
Patients with an acute ILD exacerbation, pregnant patients, those unable to hold a 10-second breath, or those requiring extra positional or expiratory imaging are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional protocol obtains two chest CT scans on the same day from patients with known ILD at two Paris hospitals and runs multiple automated quantification tools on the images. The study compares the automated extent-of-disease measurements and lung volumes between the paired scans and across different software packages. It examines whether factors such as degree of inspiration, reconstruction settings, or ILD subtype (IPF versus CTD-related ILD) affect measurement variability. The goal is to characterize the real-world reproducibility of automated ILD quantification methods.
Why it matters
Potential benefit: If successful, this work could make automated CT measurements reliable enough to help doctors track disease progression and support treatment decisions.
How similar studies have gone: Several texture-analysis and deep-learning tools have shown promising accuracy for quantifying ILD on single CT scans, but reproducibility across repeated same-day scans and different software has not been firmly established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Known interstitial lung disease as part of idiopathic pulmonary fibrosis or connective tissue disease * Followed in one of the participating hospitals * Requiring a chest CT as part of a scheduled assessment * Affiliated to a French national social security * Informed consent Exclusion Criteria: * Acute exacerbation of ILD * Pregnancy * Inability to hold an apnea for 10 seconds * Patients in the exclusion period after a previous research * Need for additional procubitus or expiratory images
Where it's running
-
APHP - Bichat hospital - Radiology
Paris, Idf, France Recruiting -
APHP - Bichat hospital - Rheumatology
Paris, Idf, France Recruiting -
APHP - Cochin Hospital - Internal medicine
Paris, Idf, France Recruiting -
APHP - Cochin Hospital - Pneumology
Paris, Idf, France Recruiting -
APHP - Cochin Hospital - Radiology
Paris, Idf, France Recruiting -
APHP - Bichat Hospital - Pneumology
Paris, Idf, France Recruiting
Study contacts
- Principal investigator: Guillaume CHASSAGNON, MD, PhD — Cochin Hospital - AP-HP
- Study coordinator: Guillaume CHASSAGNON, MD, PhD
- Email: guillaume.chassagnon@aphp.fr
- Phone: +33158414326
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Telitacicept for primary Sjögren’s with interstitial lung disease
This study tests whether Telitacicept helps people with primary Sjögren’s syndrome and interstitial lung disease compared with standard immunosuppressants.
-
Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients
This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.
-
Treprostinil Palmitil Inhalation Powder for Progressive Pulmonary Fibrosis
A 52-week study will test whether once-daily Treprostinil Palmitil Inhalation Powder helps lung function in adults with progressive pulmonary fibrosis compared to placebo.
-
Treatment Response in Myositis-Associated RP-ILD in Adults
This study tests how people with myositis and rapidly progressing interstitial lung disease respond to an immunosuppressant treatment approach.
-
AccuPulmo CT Portal for Detecting Pulmonary Fibrosis on Chest CT
This study tests how well the AccuPulmo CT Portal can identify pulmonary fibrosis on existing chest CT scans from adults at Taichung Veterans General Hospital.
-
See if 18F-FAPI-74 PET/CT can better detect fibrosis in heart and lung disease
Researchers are testing a new PET/CT tracer, 18F-FAPI-74, to see if it can reveal early fibrotic changes in people with heart and lung diseases who are at risk for tissue scarring.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.